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Abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity 
against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses 
on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS 
clinical trials. Safety and tolerability as well as practical tips for management of   side-effects, 
and drug interactions are included.
Keywords: dasatinib, resistant CML, outcomes
Introduction
Chronic myeloid leukemia (CML) is a clonal stem cell proliferative disorder,1 
  characterized by a well-recognized triphasic clinical course and by the presence of 
a hybrid oncogene, the BCR-ABL. CML patients often present during the indolent 
phase of the disease or chronic phase (CP), and evolve, in the absence of effective 
treatment, to a more resistant (accelerated phase [AP]) and rapidly fatal terminal 
phase (blast phase [BP]).2 Historically, progression to blast phase was observed in 
5%   during the first year after diagnosis, 15% in the second year and then at a rate of 
25% per year thereafter. BCR-ABL, the hallmark of CML, is the result of a reciprocal 
  translocation between chromosome 9 and 22 (the Philadelphia chromosome, or Ph+) 
which   juxtaposes two genes intimately engaged in cell signaling, signal transduction 
and cell proliferation.2,3 The ABL gene specifically encodes for nonreceptor tyrosine 
kinases, whose tightly controlled physiologic activities become deregulated and con-
stitutively active by the juxtaposition of BCR. Additionally, BCR-ABL plays a central 
role in controlling downstream pathways involved in cell proliferation, regulation of 
  cellular adhesion and apoptosis. With the observation that transduction of murine stem 
cells with   retroviral vectors containing the chimeric BCR-ABL fusion gene caused 
in mice a disease closely resembling human CML,4 targeting BCR-ABL has become 
the mainstay of modern therapy in CML.
Targeting BCR-ABL in CML
The introduction of specifically designed inhibitors of BCR-ABL tyrosine kinase 
activity has dramatically improved outcomes of CML. In 2010, patients with newly 
diagnosed CP-CML treated with the tyrosine kinase inhibitor (TKI) imatinib   mesylate 
([IM], GLEEVEC®; Novartis, East Hanover, NJ) can expect excellent chances of durable 
complete hematological ([CHR], .98%), complete cytogenetic ([CCyR], .80%), and 
major molecular responses ([MMR], .50%). These spectacular responses did translate Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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into improved 5–7 years disease-free (DFS) and overall (OS) 
survivals (83% and 90%, respectively).5,6
Resistance to IM
Despite the impressive results observed with IM, primary 
and secondary resistances to IM occur. The annual failure 
rate on IM is 3% during the first year, doubles (7%) during 
the second, and decreases in the third year (5%) and beyond.5 
However, statistics on subsequent failure rates are marred by 
patient selection biases on a trial that has lost more than 40% 
of accrued patients to follow-up once IM became commer-
cially available.5 Additionally, up to 15% of patients fail to 
achieve a major cytogenetic response 12 months after starting 
IM, which increases the risk of disease progression in the 
ensuing years.5,6 Resistance to IM is multifactorial and can 
in 50% of the cases be explained by the detection of acquired 
ABL kinase domain point mutations.7 These point mutations 
lead to stereotactic distortions of BCR-ABL that prevent IM 
from binding to its high-affinity binding site. To overcome 
these resistances, second generation tyrosine kinase inhibi-
tors were developed, some with enhanced binding affinity 
(nilotinib, Tasigna®; Novartis)8,9 others with binding affinity 
to the catalytically active state of the tyrosine kinase (dasat-
inib, Sprycel®, Bristol Myers Squibb, New York, NY, USA; 
bosutinib,10 SKI-606, Pfizer, NY).
Dasatinib
Dasatinib (DAS) is an orally bioavailable dual SRC-ABL 
inhibitor with very potent activity against BCR-ABL, the 
family of SRC kinases, ephrin receptor kinases, platelet-
derived growth factor receptor (PDGFR), cKit, as well as 
other tyrosine and tyrosine/threonine kinases.11 DAS binds 
predominantly to the ATP-binding site and to the active 
conformations of BCR-ABL.11,12 DAS’s independence from 
key residues essential for IM activity translates into improved 
activity against most mutations that confer resistance to 
IM, with the exception of T315I.12,13 DAS’s activity against 
  IM-resistant BCR-ABL+ cells was demonstrated both in vitro 
and in a mouse model of IM-resistant BCR-ABL-dependent 
disease.13 DAS inhibits phosphorylation of the BCR-ABL 
substrate CRKL in all BCR-ABL mutant cell lines with 
the exception of T315I. Certain mutations, specifically 
the F317L, did require higher concentrations of DAS to 
inhibit phosphorylation of CRKL. When severe combined 
immunodeficient mice injected with Ba/F3 cells expressing 
BCR-ABL isoforms and the firefly luciferase gene, a decrease 
in tumor burden measured by bioluminescence imaging 
was observed in DAS-treated mice harboring the wild-type 
BCR-ABL and M351T, but not the T315I mutant.13 These 
experiments laid the ground for a first in human clinical trial. 
In a Phase I trial, IM-resistant CML and Ph+ acute lympho-
blastic leukemia were enrolled on cohorts testing increasing 
doses of DAS, initially once daily, and as pharmacokinetic 
data became available, on a twice a day schedule.14 Similar 
to what was observed with IM, DAS was well-tolerated, and 
a maximum tolerated dose was not reached. The half-life 
of DAS is 3–5 hours. At doses $50 mg/d, approximately 
40% of patients had evidence of hematologic or cytogenetic 
responses.14,15 The dose schedule of 70 mg twice a day was 
subsequently selected for phase II trials.
Treatment of IM-resistant CP-CML 
with DAS
With DAS administered at 70 mg twice daily, 90% of CP 
CML with acquired resistance to IM achieve CHR within 
15 days. So far and with 2 years follow-up, major and 
CCyR are observed in 40%–50%, with progression-free 
and   overall survivals of .90% (Table 1).16,18 DAS is also 
active in CP CML with primary resistance to IM. Indeed, 
for CP CML patients with no CHR after 3 months, no cyto-
genetic response after 6 months, or no major cytogenetic 
response after 12 months of IM 400 mg/d, a switch to DAS 
(70 mg twice daily) is associated with higher CCyR (40% 
vs 16%) and MMR (16% vs 4%) as compared to a dose-
escalation of IM to 800 mg/d.19,20 The dose schedule of 70 
mg   twice-daily was re-evaluated after maturing data from the 
phase I study showed that BCR-ABL kinase inhibition was 
more sustained across a 24-hour period with the once-daily 
schedule. This observation led to a large dose-optimization 
trial that randomized IM-resistant CP-CML patients to a 
four dose schedules of DAS: 70 mg twice daily, 50 mg 
twice daily, 140 mg once daily, and 100 mg once daily.18,21 
Consistent hematologic and   cytogenetic responses were 
observed across all dose-schedule/total daily dose arms: 
CHR 85%–90%; major cytogenetic responses, 55%–60%; 
CCyR, 40%–45%.18,21 Interestingly, patients who received 
the 100 mg once daily dose experienced fewer adverse events 
(AEs) and required fewer dose interruptions. The more 
favorable safety profile combined with equivalent activity 
led to a change in the label of the approved dose for DAS 
in patients with CML-CP to 100 mg once daily.
Treatment of IM-resistant advanced 
phases CML with DAS
DAS is a very active agent in advanced phases of CML 
(Table 1).15,22–24 More than 75% of IM-resistant AP patients Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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treated with DAS 70 mg twice daily achieve a hemato-
logic response, of which approximately half are complete. 
Additionally, up to 40% of those patients also achieve a 
major cytogenetic response, a third of which are com-
plete. Responses are durable with a median 1 and 2 years 
progression-free   survival (PFS) of 68% and 52%, and over-
all survival (OS) of 80% and 70%, respectively.22,23 Initial 
responses with DAS in IM-resistant BP patients are also 
quite impressive, but short-lived. Indeed, 50% of patients 
achieve a hematologic response and 30%–50% a major 
cytogenetic response.24 However, PFS is only 3–6 months, 
and consequently OS approximates 12 months. As compared 
to CP CML, higher doses of DAS are required for advanced 
phases and no improvements in responses were observed 
when the dose of 140 mg was administered once a day or in 
two divided doses (70 mg twice daily). However, the once a 
day   regimen   demonstrated a safer toxicity profile and fewer 
dose   reductions and interruptions.23
Managing side effects of DAS
DAS is overall well tolerated. Treatment-related AEs   usually 
occur early, are reversible, and lead to   discontinuation of 
DAS in 8%–16% in patients with CP-CML, and 4%–10% 
in AP and BP patients.25 Hematologic AEs are common 
in all phases of CML, but occur more frequently in the 
advanced phases. DAS-induced cytopenias occur in the 
first 3 months of therapy, resolve 2–3 weeks after DAS is 
held, and are usually managed with standard supportive 
care (  prophylactic antibiotics, transfusions), treatment 
  interruption, and/or dose reduction. Despite the high 
  incidence of cytopenias,   neutropenic fevers are uncommon 
(,5%). In patients with advanced disease, where up to 80% 
of patients develop   pancytopenia, a bone marrow biopsy can 
help   differentiate DAS-induced cytopenia (ie, hypoplastic or 
aplastic bone   marrow) from cytopenia caused by leukemic 
marrow infiltration (hypercellular marrow with persistent 
blasts). Erythropoietin administration is not approved by the 
United States Food and Drug Administration in the setting 
of DAS-associated   anemia.   Thrombocytopenia (platelet 
level ,50 × 109/L) is less common in CP-CML with the 
100 mg once daily regimen (20% versus 45% with the 70 
mg twice daily),17,21 but can be observed in up to 80% of 
patients with advanced phases.15,22–24   Nevertheless, bleed-
ing is relatively rare occurring in ,5%.25 DAS-associated 
platelet dysfunction,26 may explain the occasional bleeding 
events that occur in the absence of thrombocytopenia. The 
most common nonhematologic AEs are gastrointestinal 
toxicities, headaches, fatigue, peripheral edema, and   pleural 
effusions.16,17,19,21–24 Nausea, vomiting, and diarrhea are 
  usually mild (grade 1/2) occurring in up to 25% of patients, 
and are manageable with supportive care agents.25 Although 
antacids and proton pump inhibitors are commonly used to 
alleviate nausea in cancer patients, these drugs should be 
avoided in DAS-treated patients as the solubility of DAS is 
pH dependent.27 Headaches and fatigue often improve with 
holding and restarting the drug at a lower dose, and do not 
necessarily recur with attempts to re-escalate the dose of 
DAS. Pleural effusions are observed in up to 10% of patients 
treated with DAS.28 The timing of onset of these exsuda-
tive effusions appears to be dose and   schedule-dependent: 
late (73 weeks) with the once daily 100 mg dose and early 
(4 weeks) in patients treated with 140 mg daily.21,29 Pleural 
effusions lead to discontinuation of DAS in 6%.28 Mecha-
nisms that lead to development of pleural effusion are not 
well understood and remain largely speculative.28 DAS 
targets pathways involved in regulation of tissue interstitial 
fluid pressure (  PDGFR-b),29,30 and permeability of pleural/
pulmonary   vasculature (SRC, YES) which may explain the 
occurrence of these effusions.29,31,32 Multivariate analyses 
have identified patients at risk for the development of 
  pleural effusions on DAS therapy. These   factors include 
older age, hypertension, prior cardiac history, a twice daily 
dose schedule, and to a certain degree, advanced phases of 
the disease.29,30 Pleural effusions should be   suspected when 
patients present with dry cough, chest   tightness, or shortness 
of breath. Given the lack of   understanding of the   underlying 
  pathophysiology of DAS-induced pleural   effusions, 
the   management remains   supportive and includes dose 
  interruption/reduction,   diuretics, low-dose corticosteroids, 
and thoracentesis for symptomatic/severe effusions.29
Table 1 Outcomes associated with treatment of iM-resistant CML with DAS according to phase of CML
CML phase  CHR MCyR/CCyR MMR Median 
follow up
PFS OS
Chronic phase16–21 91%–93% 53%–63%/50%–53% 37%–47% 24 mo 80%–86% 91%–94%
Accelerated phase22–23 45%–52% 39%–43%/32%–33% n/a 15 mo 66% 78%–82%
Blast phase24 25%–29% 33%–52%/26%–46% n/a 12 mo 3–7 mo 5–12 mo
Abbreviations: CML, chronic myeloid leukemia; CHR, complete hematological remission; MCyR, major cytogenetic remission; CCyR, complete cytogenetic remission; 
MMR, major molecular response; PFS, progression-free survival; OS, overall survival.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Drug interactions
Absorption of DAS is not affected by food.27 DAS   solubility 
is pH dependent, therefore caution should be used with 
  antacids, and proton pump inhibitors should be avoided 
during treatment with DAS. Dasatinib is a substrate for 
CYP3A4, therefore other CYP3A4 substrates, inducers, 
or inhibitors will interfere with the metabolism of DAS.27 
CYP3A4 substrates and specifically those with a   narrow 
therapeutic index such as cyclosporine and fentanyl 
simvastatin,25 may see their concentration competitively 
altered by the concurrent administration of DAS and should 
therefore be carefully monitored for specific toxicities and 
dose adjusted accordingly. CYP3A4 inducers such as with 
rifampicin, dexamethasone, St John’s Wort, phenytoin, 
and phenobarbital can decrease the blood concentration of 
DAS up to 80%.15,25,33 Finally, CYP3A4 inhibitors, such as 
ketoconazole,   macrolide antibiotics, azole antifungals, and 
grapefruit juice can increase the toxicity of DAS through an 
increase in plasma concentration. The use of anticoagulants 
or platelet inhibitors are not contraindicated, however, given 
the risk for platelet dysfunction during treatment with DAS, 
these drugs should be used with extreme caution.
Future directions
Outcomes of CML patients have improved remarkably with 
the use of targeted therapy, and for patients with disease 
resistant to IM, excellent responses with second line agents 
such as DAS can be achieved. The follow-up of DAS-treated 
patients remains relatively short, and longer follow-up 
will shed more light on the durability of these responses. 
The activity of DAS is maintained despite the presence of 
mutations that confer resistance to IM with the exception 
of the T315I mutation, and to a large degree, mutations 
affecting the residue 317 (F317L, F317V).34 The V299L 
mutation, although rarely acquired on IM, is often detected 
at the time of DAS failure.35 For those patients with the 299 
and 317 mutations detected at the time of initiation of DAS, 
other agents such as nilotinib, bosutinib (SKI606; Pfizer, 
New York, NY), or other drugs in development (INNO-406, 
AP24534), if available, should be considered.34 Alternatively, 
and with the exception of the T315I mutation, DAS can be 
successfully used as a stepping stone for allogeneic stem 
cell transplantation. The outcomes of patients allografted 
after exposure to second-line tyrosine kinase inhibitors are 
currently being analyzed in an ongoing European Bone 
Marrow Transplant registry study.36 Preliminary results have 
shown that, similar to IM,37 disease status at conditioning, 
rather than pretransplant treatment with DAS, dictates 
outcomes of transplantation. Finally, and for patients with 
no suitable donor or who are not eligible for transplantation, 
better understanding of the effects of DAS on the immune 
system may offer hopeful future alternatives. Indeed, recently 
a quite fascinating report described the development of 
clonal lymphoproliferative disorder characterized by the 
presence of large granular natural killer/T-lymphocytes in 
DAS-treated patients.38 Although a higher rate of autoimmune 
complications (pleurisy, colitis) were observed in these 
patients with clonal lymphocytic expansion, responses to 
DAS were excellent, especially for advanced phase patients, 
and unexpectedly long-lasting. Indeed, all IM-resistant or 
intolerant Ph+ acute lymphoblastic leukemia who developed 
chronic lymphocytosis after treatment with single agent DAS 
were alive 2 years after starting DAS, and 66% were still 
in remission. In contrast, median DFS and OS for patients 
without lymphocytosis were dismal, 2.7 and 5.8 months, 
respectively. Elucidating pathways that lead to this immune 
phenomenon would add an extremely potent antileukemic 
intervention to the armamentarium against CML.
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